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Introduction
Multiple myeloma (MM) is a plasma cell neoplasm characterized by the accumulation of malignant plasma cells within the bone marrow (BM). Several autocrine or paracrine factors can promote multiple myeloma cell (MMC) survival and proliferation 1, 2 . We anticipate that in the future, the inhibition of MMC growth factors may have clinical applications in combination with other drugs [3] [4] [5] [6] .
In order to identify new molecules involved in the communication between MMC and the BM environment, we compared gene expression profiles (GEP) of MMC with those of normal plasma cells, normal plasmablasts and normal peripheral blood B cells. We identified that CD200 was expressed in malignant plasma cells in 78% of newly-diagnosed patients with MM. CD200, formerly known as OX-2, is a highly conserved type I transmembrane glycoprotein that is expressed by thymocytes, activated T cells, B cells, dendritic cells, endothelial cells and neurons 7 . The expression of the receptor for CD200 (CD200R1) is described as restricted to myeloid-derived antigen presenting cells and certain populations of T cells 8 . Three other genes, closely related to CD200R1 and termed CD200R2-4 have been identified, but the function of these encoded proteins, in particular their ability to bind CD200, is not fully elucidated 9 . Several studies have shown that CD200 imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cellmediated immune responses. Increased survival of renal allografts following portal vein immunization with alloantigen correlates with an increase in CD200 expression in both hepatic and splenic dendritic cells (DCs) in a murine model 10 . Tolerance in this setting is reversed with a monoclonal antibody to CD200 In this study, we demonstrate that MMC of 78% of the patients with newly-diagnosed MM express CD200. For patients included in protocols with high dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT), the presence or absence of CD200 expression is a prognostic factor independent of ISS stage or B2M.
Materials and methods

Cell samples
XG human myeloma cell lines (HMCL) were obtained as described [14] [15] [16] . SKMM, OPM2, LP1 and RPMI8226 HMCL were purchased from ATTC (LGC Promochem, France). MMC were purified from 112 patients with newly-diagnosed MM after written informed consent was given. These 112 patients were treated with HDC and ASCT.
Seven of these 112 patients received allogenic bone marrow transplantation after 
Statistical analysis
Gene expression data were normalized with the MAS5 algorithm and analyzed with our bioinformatics platforms (RAGE, http://rage.montp.inserm.fr/ and Amazonia, http://amazonia.montp.inserm.fr/). Statistical comparisons were done with R (http://www.r-project.org/) or SPSS10 (SPSS Chicago, IL) software.
Results and Discussion
Comparing the GEP of MMC in an initial series of 48 patients with newly-diagnosed MM with the GEP of normal BM plasma cells, normal plasmablasts and normal memory B cells using Affymetrix U133 A+B DNA-microarrays, we found a clear cut expression of CD200 in MMC. In 9/48 patients, CD200 had an "absent" Affymetrix call (CD200 absent ) in MMC. In the remaining 39 patients, CD200 had a "present" call (CD200 present ) in MMC and was overexpressed in MMC compared to normal BMPC (ratio = 6.2 and P < .01), plasmablasts (ratio = 26.5 and P < .01) or memory B cells (ratio = 10 and P < .01) (Figure 1 A) . These data were confirmed with another independent series of MMC from 64 newly-diagnosed patients using Affymetrix U133 Figure S1 ). Using FACS analysis, the CD200 protein was detected on MMC in 13/15 (86%) consecutive newly-diagnosed patients, confirming the frequency of CD200 expression determined by "absent"/"present" calls with Affymetrix microarrays (Table 1) . If CD200 is expressed in MMC, the mean fluorescence intensity ranged from 364 to 8038 (Table 1 Figure S2 ).
Subsequently, we investigated the CD200 gene expression in the BM environment from patients with MM. CD200 was not expressed by CD14 monocytes, CD15 polynuclear cells and CD3 T cells that were purified from the BM of 5 newly-diagnosed patients. It is also not expressed in 7 osteoclast samples (Figure 1 A) . BM stromal cells from 5 patients with MM expressed CD200, but at a 3.9 fold lower median signal compared to that in CD200 present MMC (P = .04). CD34 + hematopoietic stem cells from 5 patients with MM expressed CD200, but at a 2.5 fold lower median signal compared to that in CD200 present MMC (P = .05).
A significantly higher number of patients with CD200 present had a monoclonal protein containing lambda-light chains, whereas an age ≥ 65 years appeared at a significantly higher frequency in patients with CD200 absent MMC (Supplementary data Table A ). In our group of 112 newly-diagnosed patients treated with HDT and ASCT, patients with CD200 absent MMC had a better event free survival (24 months) compared to patients with CD200 present MMC (14 months) ( Figure 1C ). In a Coxproportional-hazard model monitoring for the absence or presence of CD200 (P = 0.04) and ISS-stage (P = 0.01), both parameters are independently predictive for EFS (P = 0.01). If CD200 expression is tested together with classical prognostic factors, i.e. serum albumin and serum β2M, CD200 expression (P = 0.04) and B2M
(P = 0.015) remain independent prognostic factors, whereas serum albumin marginally fails to be significant (P = 0.058).
This better EFS of patients with MMC lacking CD200 could be linked to the role of CD200 in suppression of T-cell-mediated immune responses and in the development of DC with a capacity to induce Treg [9] [10] [11] 13 . A recent study has demonstrated that B cell chronic lymphocytic leukemia expresses CD200 that leads to inhibition of the Th1 response in mixed lymphocyte reactions 19 .
In conclusion, we have identified that CD200 expression by MMC is an independent prognostic factor for patients with MM that could represent a new therapeutic target. (C) Kaplan-Meier plot of the event free survival in patients with CD200 present and CD200 absent MMC.
